Epidemiology, disease burden and outcomes of cirrhosis in a large secondary care hospital in South Auckland, New Zealand

Internal Medicine Journal

Volumn 45, Issue 2, 2015, Pages 160-169

  Hsiang, J C ^a   Bai, W W ^a   Raos, Z ^a   Stableforth, W ^a   Upton, A ^a   Selvaratnam, S ^a   Gane, E J ^b   Gerred, S J ^a  

^a MIDDLEMORE HOSPITAL   (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Cirrhosis; Cirrhosis mortality; Hepatocellular carcinoma; Liver complication; Non alcoholic liver disease; Viral hepatitis

Indexed keywords

ALBUMIN; INTERFERON; PEGINTERFERON; RIBAVIRIN;

ABDOMINAL BLEEDING; ADULT; ALBUMIN BLOOD LEVEL; ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ANTIVIRAL THERAPY; ARTICLE; AUTOIMMUNE HEPATITIS; CHINESE; CHRONIC HEPATITIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; END STAGE LIVER DISEASE; ETHNIC DIFFERENCE; EUROPEAN; FEMALE; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS C; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MAORI (PEOPLE); MIDDLE AGED; MORBIDITY; MORTALITY; NEW ZEALAND; NONALCOHOLIC FATTY LIVER; OBESITY; OUTCOME ASSESSMENT; PACIFIC ISLANDER; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SECONDARY CARE CENTER; SOUTHEAST ASIAN; THROMBOCYTE COUNT; VIRUS HEPATITIS;

EID: 84964240672     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12624     Document Type: Article

References (38)

1. Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E etal. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002; 97: 2886-2895.
2. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-1832.
3. Kamper-Jorgensen M, Gronbaek M, Tolstrup J, Becker U. Alcohol and cirrhosis: dose - response or threshold effect? J Hepatol 2004; 41: 25-30.
4. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-50.
5. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C etal. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2197-2223.
6. Cooke GS, Lemoine M, Thursz M, Gore C, Swan T, Kamarulzaman A etal. Viral hepatitis and the Global Burden of Disease: a need to regroup. J Viral Hepat 2013; 20: 600-601.
7. New Zealand Census 2006. Auckland: Statistics New Zealand, 2006.
8. Robinson T, Bullen C, Humphries W, Hornell J, Moyes C. The New Zealand Hepatitis B Screening Programme: screening coverage and prevalence of chronic hepatitis B infection. N Z Med J 2005; 118: U1345.
9. Mason K, Stefanogiannis N, Templeton R, Weerasekera D, New Zealand Ministry of Health. The Health of New Zealand Adults 2011/12 Key Findings of the New Zealand Health Survey. Wellington: Ministry of Health; 2012. 1 electronic document (xi, 174 p.).
10. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA 2003; 289: 3000-3004.
11. Nesdale A Hepatitis C infection in New Zealand: estimating the current and future prevalence and impact, 2000.
12. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL etal. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-893.
13. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8: 493-496.
14. Serfaty L, Chazouilleres O, Poujol-Robert A, Morand-Joubert L, Dubois C, Chretien Y etal. Risk factors for cirrhosis in patients with chronic hepatitis C virus infection: results of a case-control study. Hepatology 1997; 26: 776-779.
15. Jepsen P, Ott P, Andersen PK, Vilstrup H. The clinical course of alcoholic cirrhosis: effects of hepatic metabolic capacity, alcohol consumption, and hyponatremia -a historical cohort study. BMC Res Notes 2012; 5: 509.
16. Marcellin P, Ziol M, Bedossa P, Douvin C, Poupon R, de Ledinghen V etal. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int 2009; 29: 242-247.
17. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F etal. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 48-54.
18. Nguyen-Khac E, Chatelain D, Tramier B, Decrombecque C, Robert B, Joly JP etal. Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests. Aliment Pharmacol Ther 2008; 28: 1188-1198.
19. Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B etal. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51: 454-462.
20. Runyon BA, Committee APG. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49: 2087-2107.
21. Bruix J, Sherman M. American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
22. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W, Practice Guidelines Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007; 46: 922-938.
23. Ministry of Health. Ethnicity Data Protocols for the Health and Disability Sector. Wellington: Ministry of Health; 2004.
24. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW etal. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
25. Roulot D, Costes JL, Buyck JF, Warzocha U, Gambier N, Czernichow S etal. Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. Gut 2011; 60: 977-984.
26. Addidle M. Impact of universal hepatitis B vaccination on antenatal hepatitis B prevalence in the Midlands region of the North Island, New Zealand. N Z Med J 2011; 124: 40-44.
27. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H etal. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531.
28. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM etal. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468-475.
29. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141: 1249-1253.
30. Hart CL, Morrison DS, Batty GD, Mitchell RJ, Davey Smith G. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. BMJ 2010; 340: c1240.
31. Pessione F, Ramond MJ, Peters L, Pham BN, Batel P, Rueff B etal. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int 2003; 23: 45-53.
32. Aertgeerts B, Buntinx F, Kester A. The value of the CAGE in screening for alcohol abuse and alcohol dependence in general clinical populations: a diagnostic meta-analysis. J Clin Epidemiol 2004; 57: 30-39.
33. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M etal. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006; 43: 1303-1310.
34. Vezali E, Aghemo A, Colombo M. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther 2010; 32: 2117-2138.
35. A special meeting review edition: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2013: The 48th Annual Meeting of the European Association for the Study of the Liver April 24-28, 2013. Gastroenterol Hepatol (NY) 2013; 9: 1-18.
36. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K etal. ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis. N Engl J Med 2014; 370: 1973-1982.
37. Ioannou GN, Weiss NS, Kowdley KV, Dominitz JA. Is obesity a risk factor for cirrhosis-related death or hospitalization? A population-based cohort study. Gastroenterology 2003; 125: 1053-1059.
38. Nguyen GC, Thuluvath PJ. Racial disparity in liver disease: biological, cultural, or socioeconomic factors. Hepatology 2008; 47: 1058-1066.